Turn Therapeutics (TTRX) Other Operating Expenses (2025 - 2026)
Turn Therapeutics (TTRX) posted quarterly Other Operating Expenses of -$286126.0 for Q1 2026, down 153.36% year-over-year from $536182.4 in Q1 2025, and down 931.31% quarter-over-quarter from -$27744.0 in Q4 2025.
Powered by 
Analysis
Turn Therapeutics (TTRX) Other Operating Expenses (2025 - 2026) Analysis & Trends
Turn Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$286126.0 for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 153.36% year-over-year to -$286126.0; the TTM figure through Mar 2026 stood at -$426801.0 (changed N/A YoY), while the FY2025 annual figure was -$928562.0, down 190.02% from the prior year.
- Other Operating Expenses for Q1 2026 stood at -$286126.0, down from -$27744.0 in the prior quarter.
- The five-year high for Other Operating Expenses was -$27744.0 in Q4 2025, with the low at -$286126.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Turn Therapeutics | 302.05 Mn | 302.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -286,126.00 |
| Mar 31, 2025 | -112,931.00 |